RadNet, Inc. (RDNT) Stock Analysis and Metrics

Sector: Healthcare Industry: Diagnostics & Research CIK: 0000790526

Market Cap 4.11 Bn

P/E -296.06

P/S 1.91

Div. Yield 0.00

ROIC (Qtr) 0.00

Total Debt (Qtr) 1.06 Bn

Revenue Growth (1y) (Qtr) 22.11

Add ratio to table...

About

RadNet Inc is a leading national provider of diagnostic imaging services in the United States operating 418 imaging centers across nine states as of December 31 2025. The company was founded in 1985 and has grown through a combination of internal development and strategic acquisitions. Its core business consists of delivering outpatient imaging exams that help physicians detect diagnose and monitor a wide range of medical conditions. The centers offer a full suite of modalities including MRI CT PET nuclear medicine mammography ultrasound Xray and...

RadNet Inc is a leading national provider of diagnostic imaging services in the United States operating 418 imaging centers across nine states as of December 31 2025. The company was founded in 1985 and has grown through a combination of internal development and strategic acquisitions. Its core business consists of delivering outpatient imaging exams that help physicians detect diagnose and monitor a wide range of medical conditions. The centers offer a full suite of modalities including MRI CT PET nuclear medicine mammography ultrasound Xray and fluoroscopy. By locating many centers in dense metropolitan areas RadNet aims to provide convenient access to high quality imaging for patients and referring physicians.

Revenue is derived mainly from two sources: fees for imaging procedures performed at company owned or jointly managed centers and sales of digital health software and services. Imaging fees are collected from third party payors such as commercial insurers managed care organizations Medicare and Medicaid as well as from patients through co pays and deductibles. The company negotiates reimbursement rates with payors and also receives direct payments for services rendered under contract with physician groups. Digital health revenue comes from the sale of RIS PACS workflow platforms AI based image analysis tools and related support and maintenance contracts. These software products are sold to hospitals health systems imaging centers and other healthcare providers in the United States and abroad. The mix of service and technology revenue helps reduce reliance on any single reimbursement stream.

The company reports its operations in two distinct business segments: Imaging Centers and Digital Health. The Imaging Centers segment encompasses all activities related to the operation of outpatient diagnostic imaging facilities. The Digital Health segment includes the development sale and support of software solutions that manage store and interpret medical images.

• The Imaging Centers segment operates 418 freestanding outpatient facilities spread across Arizona California Delaware Florida Maryland Virginia New Jersey New York and Texas. These centers provide a broad range of imaging procedures including MRI CT PET nuclear medicine mammography ultrasound Xray and fluoroscopy. Most locations offer multiple modalities allowing patients to receive several types of exams at one site. The segment generates revenue through fees billed to insurance companies government programs and individual patients for each performed study.

• The Digital Health segment creates and markets computerized systems for image storage retrieval distribution and reporting. It offers AI powered applications that assist radiologists in detecting abnormalities in mammography lung ultrasound and prostate imaging. Key products include eRad RIS PACS DeepHealth OS and tools acquired from Aidence Quantib ICAD and CIMAR. The segment serves over two thousand customers worldwide ranging from large hospital networks to small private clinics. Revenue is recognized from software licenses maintenance fees and professional services related to implementation and training.

RadNet Inc holds a leading position in the outpatient diagnostic imaging market measured by number of centers and total imaging revenue. The company is frequently cited as the largest freestanding provider of imaging services in the United States. Its scale enables it to secure favorable contracts with national and regional health plans. Competitive advantages include a diversified modality mix strong relationships with referring physician groups and a growing portfolio of digital health technologies. The firm also benefits from a disciplined acquisition strategy that adds volume and geographic depth while integrating operations to achieve cost savings.

The company serves a diverse customer base that includes individual patients seeking diagnostic exams and their referring physicians who order the studies. Hospitals and health systems contract with RadNet both for imaging center joint ventures and for the purchase of digital health software. Insurers such as commercial carriers Medicare and Medicaid pay for services rendered to their members. Additionally the company works with employer groups and occupational health providers that require imaging for workforce health programs. While specific customer names are not disclosed in the filing the breadth of relationships underscores the company’s reach across the healthcare ecosystem.

Investment thesis

Bull case

RadNet’s third‑quarter revenue surged 13.4% to a new record, driven by a 28.2% share of advanced imaging volume that rose 13.0% YoY. The company’s advanced imaging mix is a critical catalyst because advanced studies such as PET‑CT, PSMA and amyloid brain scans have higher reimbursement and lower competition than routine imaging, creating a sustainable margin moat. Management’s emphasis on TechLive and dynamic scheduling has translated into a 42% reduction in exam‑room closures, demonstrating that technology can unlock real capacity gains without additional fixed capital. This operational leverage is reflected in the 26‑basis‑point EBITDA margin expansion, suggesting that future volume growth can be more efficiently translated into profitability.
The acquisition of iCAD was fully integrated within three months, bringing an immediate $5 million of digital‑health revenue to the books and generating a 112% YoY growth in AI‑powered breast‑cancer detection revenue. iCAD’s ProFound suite complements RadNet’s DeepHealth platform, creating a unified AI ecosystem that can be cross‑sold to existing centers and external customers. The “very substantial sales force” that now backs iCAD has already begun to capture new customer wins, implying that the acquisition is not a mere add‑on but a revenue engine that can expand across all 400+ facilities. As AI adoption accelerates in radiology, this early market capture positions RadNet to be a leader in software‑enabled imaging, a transition the company’s CEO explicitly predicts will dominate the industry.
Digital health revenue grew 51.6% YoY, with AI revenue alone up 112%. The company has a 45%+ national adoption rate for its Enhanced Breast Cancer Detection program, and larger capitated groups are adding the program as a covered benefit for over 700,000 members. This high penetration not only boosts top‑line growth but also improves payer mix, shifting revenue toward higher‑paying fee‑for‑service contracts. The near‑term opportunity is the upcoming launch of new FDA‑cleared AI modules (e.g., breast‑ultrasound AI) that can immediately be deployed across RadNet’s network, further expanding scope and price‑point. The company’s integrated “DeepHealth OS” framework offers a scalable platform that can be monetized to third parties, opening a significant B2B revenue stream beyond internal service.
Medicare is a critical revenue driver, accounting for roughly 23‑24% of current business. Management’s analysis of the 2026 physician fee schedule indicates a net benefit of $4‑$5 million in revenue, breaking a five‑year trend of cuts. This positive adjustment is largely mechanical, driven by a 3.3% increase in the conversion factor, and should be realized without further negotiation, giving RadNet a predictable uplift. Because Medicare reimbursement is relatively stable and immune to the payer churn affecting commercial contracts, the company’s cash‑flow sensitivity to payer mix is mitigated. The predictable Medicare upside provides a cushion against any short‑term volatility in other segments.
RadNet’s facility count has reached 407, with five new centers added in 2025 and additional acquisitions in the pipeline. The company’s strategy of combining de‑novo openings with tuck‑in acquisitions allows it to scale efficiently, often closing the acquisition and integration process in less than a year. The network effect is evident: with more centers, the company can spread fixed costs, negotiate better rates, and offer more comprehensive services to health systems. The management team has demonstrated an ability to close deals quickly and integrate technology (e.g., TechLive, AlphaRT) with minimal disruption, preserving the quality of patient experience. Continued facility expansion aligns with the broader industry shift from hospital‑based to ambulatory imaging, a trend that should sustain demand for RadNet’s services.

RadNet’s third‑quarter revenue surged 13.4% to a new record, driven by a 28.2% share of advanced imaging volume that rose 13.0% YoY. The company’s advanced imaging mix is a critical catalyst because advanced studies such as PET‑CT, PSMA and amyloid brain scans have higher reimbursement and lower competition than routine imaging, creating a sustainable margin moat. Management’s emphasis on TechLive and dynamic scheduling has translated into a 42% reduction in exam‑room closures, demonstrating that technology can unlock real capacity gains without additional fixed capital. This operational leverage is reflected in the 26‑basis‑point EBITDA margin expansion, suggesting that future volume growth can be more efficiently translated into profitability.
The acquisition of iCAD was fully integrated within three months, bringing an immediate $5 million of digital‑health revenue to the books and generating a 112% YoY growth in AI‑powered breast‑cancer detection revenue. iCAD’s ProFound suite complements RadNet’s DeepHealth platform, creating a unified AI ecosystem that can be cross‑sold to existing centers and external customers. The “very substantial sales force” that now backs iCAD has already begun to capture new customer wins, implying that the acquisition is not a mere add‑on but a revenue engine that can expand across all 400+ facilities. As AI adoption accelerates in radiology, this early market capture positions RadNet to be a leader in software‑enabled imaging, a transition the company’s CEO explicitly predicts will dominate the industry.
Digital health revenue grew 51.6% YoY, with AI revenue alone up 112%. The company has a 45%+ national adoption rate for its Enhanced Breast Cancer Detection program, and larger capitated groups are adding the program as a covered benefit for over 700,000 members. This high penetration not only boosts top‑line growth but also improves payer mix, shifting revenue toward higher‑paying fee‑for‑service contracts. The near‑term opportunity is the upcoming launch of new FDA‑cleared AI modules (e.g., breast‑ultrasound AI) that can immediately be deployed across RadNet’s network, further expanding scope and price‑point. The company’s integrated “DeepHealth OS” framework offers a scalable platform that can be monetized to third parties, opening a significant B2B revenue stream beyond internal service.
Medicare is a critical revenue driver, accounting for roughly 23‑24% of current business. Management’s analysis of the 2026 physician fee schedule indicates a net benefit of $4‑$5 million in revenue, breaking a five‑year trend of cuts. This positive adjustment is largely mechanical, driven by a 3.3% increase in the conversion factor, and should be realized without further negotiation, giving RadNet a predictable uplift. Because Medicare reimbursement is relatively stable and immune to the payer churn affecting commercial contracts, the company’s cash‑flow sensitivity to payer mix is mitigated. The predictable Medicare upside provides a cushion against any short‑term volatility in other segments.
RadNet’s facility count has reached 407, with five new centers added in 2025 and additional acquisitions in the pipeline. The company’s strategy of combining de‑novo openings with tuck‑in acquisitions allows it to scale efficiently, often closing the acquisition and integration process in less than a year. The network effect is evident: with more centers, the company can spread fixed costs, negotiate better rates, and offer more comprehensive services to health systems. The management team has demonstrated an ability to close deals quickly and integrate technology (e.g., TechLive, AlphaRT) with minimal disruption, preserving the quality of patient experience. Continued facility expansion aligns with the broader industry shift from hospital‑based to ambulatory imaging, a trend that should sustain demand for RadNet’s services.

Bear case

RadNet’s top‑line growth is heavily concentrated in the advanced imaging segment, which remains vulnerable to changes in payer policy and reimbursement rates. While the company has reported a 13% volume growth, a contraction in advanced imaging reimbursement—particularly in the Medicare mix—could materially erode margins, as the higher‑acuity services are also the most susceptible to rate cuts. The management’s optimistic outlook on Medicare is based on a single year’s favorable schedule; any future policy shift or unexpected cuts could reverse the projected $4‑$5 million uplift and expose the business to revenue volatility.
The digital‑health segment, although growing 51.6% YoY, is still nascent and faces significant margin uncertainty. The iCAD acquisition was priced at $5 million in stock and has historically contributed negative EBITDA, implying that the company may need to support it with cash for several years before it turns profitable. Moreover, the integration of AI platforms requires continuous investment in data governance, compliance, and regulatory approvals, which could erode the projected cost synergies and delay revenue realization.
RadNet’s capital‑expenditure guidance has increased by $5 million, signaling a continued need to invest in physical infrastructure. The expansion to 407 facilities requires ongoing maintenance, equipment upgrades, and regulatory compliance costs that could offset the incremental revenue gains. If the company’s growth in new centers slows or if market saturation occurs in key regions, the capital outlay may become a drag on cash flow and return on investment, especially given the company’s already modest net debt to EBITDA ratio that leaves little room for margin erosion.
The company’s workforce stability is a recurring theme in the call, yet it remains a persistent risk. Although the management claims labor market pressures have eased, the industry still faces significant shortages of technologists and radiologists, driving up labor costs and increasing reliance on overtime or temporary staffing. The AlphaRT platform, while offering remote staffing, introduces complexity in credentialing, quality control, and compliance across multiple states, which could result in legal liabilities or reputational risk if not managed properly.
RadNet’s dependence on a limited payer mix—primarily Medicare, commercial, and capitated contracts—exposes it to payer concentration risk. The company has only 2.5% exposure to Medicaid fee‑for‑service, but its commercial portfolio is concentrated in large capitated groups that may renegotiate terms or switch to competitors. If these groups pursue alternative imaging partners or shift to integrated health systems that prefer in‑house imaging, RadNet could lose a significant portion of its referral base, eroding volume and margin.

RadNet’s top‑line growth is heavily concentrated in the advanced imaging segment, which remains vulnerable to changes in payer policy and reimbursement rates. While the company has reported a 13% volume growth, a contraction in advanced imaging reimbursement—particularly in the Medicare mix—could materially erode margins, as the higher‑acuity services are also the most susceptible to rate cuts. The management’s optimistic outlook on Medicare is based on a single year’s favorable schedule; any future policy shift or unexpected cuts could reverse the projected $4‑$5 million uplift and expose the business to revenue volatility.
The digital‑health segment, although growing 51.6% YoY, is still nascent and faces significant margin uncertainty. The iCAD acquisition was priced at $5 million in stock and has historically contributed negative EBITDA, implying that the company may need to support it with cash for several years before it turns profitable. Moreover, the integration of AI platforms requires continuous investment in data governance, compliance, and regulatory approvals, which could erode the projected cost synergies and delay revenue realization.
RadNet’s capital‑expenditure guidance has increased by $5 million, signaling a continued need to invest in physical infrastructure. The expansion to 407 facilities requires ongoing maintenance, equipment upgrades, and regulatory compliance costs that could offset the incremental revenue gains. If the company’s growth in new centers slows or if market saturation occurs in key regions, the capital outlay may become a drag on cash flow and return on investment, especially given the company’s already modest net debt to EBITDA ratio that leaves little room for margin erosion.
The company’s workforce stability is a recurring theme in the call, yet it remains a persistent risk. Although the management claims labor market pressures have eased, the industry still faces significant shortages of technologists and radiologists, driving up labor costs and increasing reliance on overtime or temporary staffing. The AlphaRT platform, while offering remote staffing, introduces complexity in credentialing, quality control, and compliance across multiple states, which could result in legal liabilities or reputational risk if not managed properly.
RadNet’s dependence on a limited payer mix—primarily Medicare, commercial, and capitated contracts—exposes it to payer concentration risk. The company has only 2.5% exposure to Medicaid fee‑for‑service, but its commercial portfolio is concentrated in large capitated groups that may renegotiate terms or switch to competitors. If these groups pursue alternative imaging partners or shift to integrated health systems that prefer in‑house imaging, RadNet could lose a significant portion of its referral base, eroding volume and margin.

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	27,360.50 Bn	42.27	7,256.31	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	166.69 Bn	24.59	3.69	43.16 Bn
3	DHR	Danaher Corp /De/	116.47 Bn	31.82	4.70	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.38 Bn	38.84	9.53	0.83 Bn
5	A	Agilent Technologies, Inc.	32.06 Bn	24.90	4.54	0.30 Bn
6	IQV	Iqvia Holdings Inc.	28.74 Bn	20.99	1.73	15.83 Bn
7	NTRA	Natera, Inc.	27.83 Bn	-121.42	11.13	0.02 Bn
8	ILMN	Illumina, Inc.	21.92 Bn	25.95	4.99	1.49 Bn

Research Tools

RadNet, Inc. (NASDAQ: RDNT)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Research Tools

RadNet, Inc. (NASDAQ: RDNT)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password